Our fast-tracked, molecular, biomarker-led screening and patient enrolment from the entire nation are greatly reducing costs as well as time from bench to bedside.
Make your trials cheaper and faster to run
Get access to 25,000 screened patients
Identify the right patients and the right trials
Draw on the knowledge and expertise of our network
Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.
CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.
Omico’s landmark Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) aims to open up new options for patients with difficult-to-treat, advanced and metastatic cancers.
Through our Cancer Screening Project (CaSP) we’re performing comprehensive genomic profiling for cancer patients with unmet clinical need to match them to clinical trials or other care pathways.
Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy.
We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.
Our Surveillance study in Multi-Organ Cancer-prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high risk of multi-organ cancer.
